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ABSTRACT
Farnesoid X receptor (FXR, NR1H4) is a member of the nuclear receptor
superfamily of ligand-activated transcription factors. Since the role of FXR in osteoclast
differentiation remains ill-defined, we investigated the biological function of FXR on
osteoclastogenesis, using FXR-deficient mice. We demonstrated that FXR deficiency
increases osteoclast formation in vitro and in vivo. First, FXR deficiency was found to
accelerate osteoclast formation via down-regulation of c-Jun N-terminal kinase (JNK)
1/2 expression. Increased expression of peroxisome proliferator-activated receptor
(PPAR)γ and peroxisome proliferator-activated receptor gamma coactivator 1 (PGC1)β seems to mediate the pro-osteoclastogenic effect of FXR deficiency via the JNK
pathway. In addition, we found that FXR deficiency downregulated the expression of
interferon-β (IFN-β), a strong inhibitor of osteoclastogenesis, via receptor activator
of nuclear factor-kappaB ligand (RANKL). We further suggested that interference of
IFN-β expression by FXR deficiency impaired the downstream JAK3-STAT1 signaling
pathways, which in turn increased osteoclast formation. Finally, FXR deficiency
accelerated unloading- or ovariectomy-induced bone loss in vivo. Thus, our findings
demonstrate that FXR is a negative modulator in osteoclast differentiation and identify
FXR as a potential therapeutic target for postmenopausal osteoporosis and unloadinginduced bone loss.

INTRODUCTION

macrophages (BMMs) differentiate into tartrate-resistant
acid phosphatase (TRAP)-positive pre-osteoclasts, which
then fuse with each other to form mature osteoclasts [4–6].
Macrophage colony-stimulating factor (M-CSF)
and receptor activator of nuclear factor kappa-B ligand
(RANKL) provide the two necessary and sufficient
signals for osteoclast differentiation. Binding of M-CSF
to its receptor, CSF-1R, in osteoclast precursors promotes
their proliferation and survival via the activation of
kinases such as Src, phospholipase C-gamma (PLC-γ),
phosphoinositide 3-kinase (PI3K), protein kinase B (PKB,
also AKT) and extracellular signal-regulated kinase 1/2

Bone is consistently renewed throughout life by
the opposing activities of osteoblastic bone formation
and osteoclastic bone resorption pathways. Although
osteoclasts are required for bone remodeling, excess
activity of osteoclasts can lead to various diseases
such as periodontal disease, osteoporosis, rheumatoid
arthritis, multiple myeloma, and metastatic cancers [1–3].
Osteoclasts are giant multinucleated cells derived from
hematopoietic precursors of the monocyte-macrophage
lineage. During osteoclastogenesis, bone marrow-derived
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(ERK1/2) [7–9]. RANKL binding to RANK induces the
association of RANK with tumor necrosis factor receptorassociated factor 6 (TRAF6), which activates nuclear
factor-kappaB (NF-κB) and mitogen-activated protein
kinases (MAPKs; ERK1/2, p38, and stress-activated
protein kinase/c-Jun N-terminal kinase (SAPK/JNK)). In
turn, these kinases activate nuclear factor of activated T
cells (NFATc1), the master transcription factor responsible
for osteoclast differentiation and function [10].
The farnesoid X receptor (FXR, NR1H4) is
a member of the nuclear receptor superfamily of
transcription factors that regulates multiple biological
processes. Bile acid has been identified as endogenous
ligands for FXR [11–13]. Upon ligand-induced activation,
FXR binds to FXR response elements [14] either as a
monomer or as a heterodimer with the retinoid X receptor
(RXR) [13, 14] and modulates bile acids, lipid and glucose
metabolism, inflammation, and energy metabolism
[11, 12]. Given all of these benefits, FXR has been
considered as a therapeutic target for the treatment of
metabolic disorders [19, 20].
Several studies suggest that FXR has complex
roles in the pathogenesis of metabolic dysfunction,
and its activity in different tissues could possibly exert
different effects on metabolism [11–20]. We previously
demonstrated that the deletion of FXR (FXR−/−) in vivo
resulted in a significant reduction in bone mineral density
compared with that in FXR+/+ mice [21]. Since the
mechanism by which FXR modulates bone metabolism
has not been fully explored, we investigated a specific
role of FXR in the modulation of osteoclastogenesis and
bone loss in vitro and in vivo. Our work demonstrates that
FXR could be exploited to prevent the development of
osteoclast-associated bone diseases.

the control vector (Figure 1D). In accordance with these
results, overexpression of FXR attenuated the RANKLinduced expression of NFATc1 during RANKL-mediated
osteoclastogenesis (Figure 1E). Taken together, these
data suggested that FXR has a negative role in RANKLmediated osteoclast differentiation.
To further investigate the role of FXR on osteoclast
formation in vivo, we conducted histomorphometric
analyses of bone sections from the distal femur of FXR+/+
and FXR−/− mice. FXR deficiency increased the number
of osteoclasts per bone surface (N.Oc/BS; Figure 1F).
Both the number of TRAP+ mononuclear cells (N.Mo.
TRAP+ cells/BS) and multinuclear osteoclasts (N.Mu.
Oc/BS) per bone surface were increased in FXR−/−
compared with FXR+/+ femur (Figure 1G and 1H). FXR
deficiency also enhanced the levels of osteoclast surface
per bone surface (Oc.S/BS; Figure 1I). These observations
indicate that FXR deficiency increases osteoclastogenesis
in vivo. Furthermore, the role of FXR in the context of
inflammation-induced osteoclastogenesis was examined
using the lipopolysaccharide (LPS)-challenged bone loss
model. LPS stimulates osteoclast formation in vivo. When
LPS was injected into the supra calvaria region of mice,
the number of TRAP stained-osteoclasts was markedly
increased in the calvaria of FXR−/− compared with that
of FXR+/+ mice (Figure 1J, 1K). Collectively, these
results suggest that FXR is a crucial negative regulator of
osteoclast differentiation.

FXR deficiency accelerates osteoclast formation
via downregulation of JNK 1/2 expression
To clarify the mechanism of increased
osteoclastogenesis by FXR deletion, we performed in
vitro experiments, using BMMs isolated from FXR−/− and
FXR+/+ mice. We first showed that FXR−/− BMMs exhibited
more TRAP+ MNCs by RANKL in a dose-dependent
manner, in comparison to FXR+/+ BMMs (Figure 2A). In
addition, when cultured on dentine slices with RANKL,
FXR−/− BMMs generated more resorption pits than
FXR+/+ BMMs, with larger overall area (Figure 2B).
To examine the mechanisms underlying the
osteoclastogenic increase in FXR−/− BMMs, we
investigated the expression of NFATc1, a key regulator of
osteoclast differentiation. There was a higher increase in
the expression level of NFATc1 by RANKL in FXR−/−
BMMs than in FXR+/+ BMMs (Figure 2C). Next, we
investigated the role of FXR in the regulation of RANKLdependent signaling pathways, including ERK, p38,
JNK1/2, NF-κB, and AKT. There was no significant
difference in ERK, p38, NF-κB, and AKT activation by
RANKL between FXR+/+ and FXR−/− BMMs (data not
shown). In contrast, JNK1/2 phosphorylation by RANKL
was suppressed in FXR−/− BMMs with a substantial
change in protein expression (Figure 2D). The reduction
of JNK1/2 protein expression in FXR−/− BMMs was

RESULTS
FXR deficiency facilitates osteoclast
differentiation
To explore the functional role of FXR in osteoclast
differentiation, we first examined the endogenous
expression of FXR in BMMs by RANKL. The mRNA
and protein expression levels of FXR were significantly
decreased in BMMs by RANKL treatment (Figure 1A,
1B). Thus, we investigated the role of FXR on RANKLinduced osteoclast formation, using an activator and an
inhibitor of FXR. Activation of FXR by chenodeoxycholic
acid (CDCA) decreased the formation of TRAP+
multinucleated cells (MNCs), whereas inhibition of
FXR by guggulsterone significantly enhanced the
formation of TRAP+ MNCs by RANKL (Figure 1C). We
next overexpressed FXR in BMMs, using a retrovirus
(Supplementary Figure 1). Overexpression of FXR in
BMMs signiﬁcantly inhibited the formation of TRAP+
MNCs mediated by RANKL when compared with that in
www.impactjournals.com/oncotarget
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due to decreased JNK1/2 mRNA levels (Figure 2E).
Modulation of JNK1/2 expression levels was further
confirmed by pharmacological activation (CDCA) or

inhibition (guggulsterone) of FXR (Figure 2F), and
by overexpression of FXR (Supplementary Figure 2).
Paradoxically, JNK is known to be critical for RANKL-

Figure 1: FXR negatively regulates osteoclast formation. (A) BMMs from 12-week-old mice were cultured with RANKL (100

ng/ml) and M-CSF (30 ng/ml) for 4 days. The mRNA levels of FXR were analyzed by real-time PCR. (B) BMMs from 12-week-old mice
were cultured with RANKL (100 ng/ml) for the indicated times and FXR expression levels were analyzed by western blot. (C) BMMs
were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) in the presence of 75 μM CDCA or 0.3 μM guggulsterone for 4 days.
TRAP+ MNCs were counted as osteoclasts when more than 3 nuclei were present. Scale bar, 200 μm. (D) BMMs were infected by mock or
FXR through a retrovirus packaging system. Infected BMMs were cultured with RANKL (100 ng/ml) and M-CSF (30 ng/ml) for 4 days.
Scale bar, 200 μm. (E) Infected BMMs were cultured with M-CSF (30 ng/ml) in the presence or absence of RANKL (200 ng/ml) for 48
h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. (F–I) Histological bone sections from distal femur
of FXR+/+ and FXR−/−mice were analyzed. N.Oc./BS (F), N.Mo. TRAP+ cells/BS (G), N.Mu.Oc/BS (H) and Oc.S/BS (I). n = 6 for each
group. (J–K) Calvarias of FXR+/+ and FXR−/− mice that received the vehicle or LPS were subjected to TRAP staining. TRAP+ stained area
in calvaria was quantified using ImageJ. Representative images are shown in (K). n = 5 for each group. Scale bar, 500 μm. *p < 0.05, **p
< 0.01. N.Oc./BS: osteoclast number/bone surface; N.Mo.TRAP+ cells/BS: number of TRAP+ mononuclear cells/bone surface; N.Mu.Oc/
BS: number of multinuclear osteoclast/bone surface; Oc.S/BS: osteoclast surface/bone surface.
www.impactjournals.com/oncotarget
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Since FXR−/− BMMs have higher expression levels
of PPARγ and PGC-1β compared to FXR+/+ BMMs, we
investigated the effect of rosiglitazone, a PPARγ agonist,
on RANKL-induced osteoclast differentiation from BMM
cells. As previously reported [30], rosiglitazone increased
osteoclast formation from FXR+/+ BMMs, and this
induction was accelerated in FXR−/− BMMs (Figure 3G).
We also revealed that the level of NFATc1 was increased
by rosiglitazone in FXR+/+ cells, but was significantly
higher in FXR−/− cells (Figure 3H). These data suggest
that up-regulation of PPARγ and PGC-1β expression by
suppression of the JNK pathway leads to the increased
osteoclast formation in FXR−/− BMMs.

stimulated NFATc1 induction and osteoclast formation
[2–4]. Thus, we investigated whether pharmacological
JNK inhibition by SP600125 or down-regulation of JNK
by siRNA would closely mimic the genetic deletion of
FXR. Since the basal level of JNK1/2 phosphorylation
was maintained in FXR−/− BMMs by RANKL (Figure 2D),
we used a lower concentration (0.3 μM) of SP600125 than
is normally used (1–10 μM). Interestingly, a low level of
JNK1/2 inhibition led to a strong increase in osteoclastic
differentiation by RANKL accompanied by a significant
induction of NFATc1 (Figure 2G, 2H). Similar effects
were seen by the use of siRNAs. The introduction of
JNK-specific siRNA into FXR+/+ BMMs showed a similar
reduction in JNK1/2 mRNA expression similar to that in
FXR−/− BMMs (Supplementary Figure 3). Compared to
that with the control siRNA, the knock-down of JNK1/2
resulted in a significant increase in NFATc1 expression
as well as in the formation of TRAP+ MNCs by RANKL
(Figure 2I, 2J). These results indicate that FXR has a
negative role in osteoclast differentiation by modulating
JNK signals downstream to RANKL.

FXR deficiency accelerates rosiglitazone-induced
bone loss in vivo
To further delineate the effect of increased
PPARγ and PGC-1β expression in FXR−/− BMMs
on bone resorption and bone loss in vivo, we orally
administrated FXR+/+ or FXR−/− mice with rosiglitazone
or vehicle at 10 mg/kg/d for 8 weeks. Femurs from the
rosiglitazone group became darker in FXR−/− mice than
in FXR+/+ mice (Figure 4A). The DXA analysis indicated
that rosiglitazone-mediated reduction in BMD was
significantly accelerated in the femurs of FXR−/− mice
(Figure 4B). A micro-CT analysis of the metaphyseal
region of the femur showed that the trabecular bone
volume per tissue volume (BV/TV) was significantly
lower in FXR−/− than FXR+/+ mice following rosiglitazone
treatment (Figure 4C). Consistently, two other bone
parameters related to BV/TV – trabecular thickness
(Tb.Th) and trabecular number (Tb.N; linear density of
trabecular bone) – were more significantly reduced in
FXR−/− mice compared with FXR+/+ mice by rosiglitazone
treatment (Figure 4D, 4E). No obvious difference was seen
in trabecular separation (Tb.Sp) between rosiglitazonetreated FXR+/+ and FXR−/− mice (Figure 4F). Rosiglitazone
treatment also resulted in a high structure model index
(SMI) in FXR+/+ mice, an indicator of increased fragility,
which was more significantly increased in FXR−/− mice
(Figure 4G). Finally, two-dimensional visualization of
the femoral area clearly showed that the massive loss of
trabecular bone following rosiglitazone treatment was
much higher in FXR−/− mice compared with FXR+/+ mice
(Figure 4H). These results indicate that FXR deficiency
confers sensitivity to rosiglitazone-induced bone
resorption and bone loss in vivo.

FXR deficiency up-regulates PPARγ and PGC1β expression via the JNK pathway
To gain insight into how FXR modulates osteoclast
formation via JNK, we investigated the expression of
genes known to have a role in osteoclastogenesis. We
found that JNK inhibitor (0.3 μM) or JNK-specific
siRNA enhanced the mRNA expression of peroxisome
proliferator-activated receptor (PPAR)γ and peroxisome
proliferator-activated receptor-gamma coactivator 1 (PGC1) β in BMMs (Figure 3A, 3B). Furthermore, activation of
FXR by CDCA decreased the mRNA expression of PPARγ
and PGC-1β, whereas inhibition of FXR by guggulsterone
conversely resulted in an increase in these mRNA
expressions (Figure 3C). Real-time PCR demonstrated
that the mRNA expression of PPARγ and PGC-1β was
significantly increased in FXR−/− BMMs compared with
that in FXR+/+ BMMs, which is consistent with these
results (Figure 3D, 3E). Moreover, RANKL-induced
mRNA expression levels of PPARγ and PGC-1β were
maintained at significantly higher levels in FXR−/− BMMs
(Figure 3D, 3E). Similarly, the up-regulation of PPARγ
protein expression in FXR−/− BMMs was confirmed by
western blot (Figure 3F).
PPARγ is a member of the nuclear hormone receptor
superfamily of ligand-responsive transcription factors that
can be activated by lipophilic ligands. PPARγ activation
by rosiglitazone promotes hematopoietic stem cell (HSC)
differentiation into osteoclasts, thus increasing bone
resorption [24, 25]. PGC-1β is a transcriptional coactivator
that regulates energy metabolism by stimulating
mitochondrial biogenesis and respiration of cells [26–29].
PGC-1β is required for the pro-osteoclastogenic and bone
resorption-enhancing effects of PPARγ [24].
www.impactjournals.com/oncotarget
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via downregulation of IFN-β signaling pathways
To balance out osteoclastogenesis, RANKL also
induces the IFN-β gene in BMMs, and this induction
constitutes a critical aspect of the negative feedback
regulation of RANKL signaling that allows for the
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Figure 2: FXR deficiency increases osteoclast differentiation via downregulation of JNK1/2 expression. (A) BMMs from

FXR+/+ and FXR−/− mice were cultured with M-CSF and the indicated concentration of RANKL for 4 days, and TRAP+ osteoclasts were
counted. (B) BMMs from FXR+/+ and FXR−/− mice were placed on dentine slices and cultured in the presence of RANKL (100 ng/ml) for 6
days. The remaining cells were removed and stained with toluidine blue. The images were observed under the microscope. The number of
resorbed pits was counted and pit area in each dentine was quantified using ImageJ. (C) BMMs from FXR+/+ and FXR−/− mice were cultured
with RANKL (200 ng/ml) for the indicated time. (D) BMMs from FXR+/+ and FXR−/− mice were serum-starved for 16 h and stimulated
with RANKL (200 ng/ml) for the indicated time. Cell lysates were then subjected to western blot analysis with anti-NFATc1, anti-p-JNK, or
anti-JNK antibody. (E) The mRNA expression of JNK1 and JNK2 in FXR+/+ and FXR−/− BMMs was analyzed by real-time PCR. (F) FXR+/+
BMMs were cultured in the presence of 75 μM CDCA or 0.3 μM guggulsterone for 48 h. The mRNA expression of JNK1 and JNK2 was
analyzed by real-time PCR. (G) FXR+/+ BMMs were cultured with RANKL (100 ng/ml) in the presence or absence of SP600125 (0.3 μM),
a JNK inhibitor, for 4 days. (H) FXR+/+ BMMs were cultured with RANKL (200 ng/ml) in the presence or absence of SP600125 (0.3 μM)
for 48 h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. (I) FXR+/+ BMMs were transfected with 40
nM siRNA. The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for 3 days, and then TRAP+ osteoclasts were
counted. (J) The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for 48 h. Cell lysates were then subjected to
western blot analysis with anti-NFATc1 antibody. Data are expressed as means ± SD from at least three independent experiments. Scale
bar, 200 μm. *p < 0.05.
www.impactjournals.com/oncotarget
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Figure 3: FXR deficiency up-regulates PPARγ and PGC-1β expression via downregulation of JNK. (A) FXR+/+ BMMs

were cultured in the presence or absence of SP600125 (0.3 μM) for 24 h. The mRNA expression of PPARγ or PGC-1β was analyzed by realtime PCR. (B) FXR+/+ BMMs were transfected with 40 nM siRNA. The mRNA expression was analyzed by real-time PCR using PPARγ
or PGC-1β primer. (C) FXR+/+ BMMs were cultured with CDCA (75 μM) or guggulsterone (0.3 μM) for 24 h. The mRNA expression of
PPARγ or PGC-1β was analyzed by real-time PCR. (D–E) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml)
for the indicated time. The mRNA level was analyzed by real-time PCR with PPARγ (D) or PGC-1β (E) primer. (F) FXR+/+ and FXR−/−
BMMs were cultured with RANKL (200 ng/ml) for the indicated time. Cell lysates were then subjected to western blot analysis with
anti-PPARγ antibody. (G) FXR+/+ and FXR−/− BMMs were cultured with RANKL (100 ng/ml) in the presence or absence of rosiglitazone
(0.3 μM) for 3 days. Scale bar, 200 μm. (H) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml) in presence or
absence of rosiglitazone (0.3 μM) for 48 h. Cell lysates were then subjected to western blot analysis with anti-NFATc1 antibody. Data are
expressed as means ± SD from at least three independent experiments. *p < 0.05, **p < 0.01.
www.impactjournals.com/oncotarget
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and this induction was significantly decreased in FXR−/−
BMMs (Figure 5A). The phosphorylation of STAT1 is
known to be essential for IFN-β signaling by RANKL
[31]. The level of p-STAT1 by RANKL was increased
in FXR+/+ BMMs, which was completely abrogated in
FXR−/− BMMs (Figure 5B). In accord with these findings,

suppression of excessive osteoclastogenesis [31].
Since FXR deficiency was shown to increase the
pro-osteoclastogenic signals from RANKL, we next
investigated whether FXR deficiency modulates the
anti-osteoclastogenic mechanism of RANKL. RANKL
increased mRNA expression of IFN-β in FXR+/+ BMMs,

Figure 4: FXR deficiency increases rosiglitazone-induced bone loss in vivo. Male 12-week-old FXR+/+ and FXR−/− mice were

orally administered daily with rosiglitazone (10 mg/kg) for 2 months, and mouse femurs were collected. (A) Femurs of FXR+/+ or FXR−/−
mice from each group. (B) BMD (g/cm2) of femurs from FXR+/+ and FXR−/− mice was analyzed by DXA. (C–G) Various bone parameters
were analyzed by micro-CT. BV/TV (%) (C), Tb.Th (mm) (D), Tb.N (/mm) (E), Tb.Sp (mm) (F), SMI (G). (H) Two-dimensional micro-CT
images of the distal metaphysis of the femurs. *p < 0.05, **p < 0.01. BMD, bone mineral density; BV/TV, bone volume per tissue volume;
Tb.Th, trabecular thickness; Tb.N, trabecular number; Tb.Sp, trabecular separation; SMI, structural model index.
www.impactjournals.com/oncotarget
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overexpression of FXR in BMMs increased the level of
IFN-β and p-STAT1 by RANKL when compared with the
results with control vector (Figure 5C, 5D). The STAT
family is located downstream of the JAKs [30]. We further
demonstrated that RANKL increases JAK3 mRNA and
protein levels in FXR+/+ BMMs, but not in FXR−/− BMMs
(Figure 5E, 5F).
Since the role of JAK3 in osteoclast formation has
not been determined [32], we next assessed the effect of
JAK3 downregulation on osteoclast differentiation. We
found that a pharmacological JAK3 inhibitor accelerates
RANKL-induced osteoclastogenesis in a dose-dependent
manner (Figure 5G). Similar effects were seen in BMMs
transfected with JAK3-specific siRNA (Figure 5H). In
addition, compared with the control, knock-down of JAK3
in BMMs resulted in a significant decrease in the level
of p-STAT1 (Figure 5I), followed by increased NFATc1
expression by RANKL (Figure 5J). These data suggest
that the impairment of IFN-β pathways via JAK3-STAT1
is another mechanism underlying the increased osteoclast
formation in FXR−/− BMMs.

To further investigate the role of FXR in estrogen
withdrawal-induced bone loss, we examined FXR+/+ and
FXR–/– mice that were subjected to sham or OVX in vivo.
Ten weeks after OVX, bone loss was even more severe
in FXR–/– mice than in FXR+/+ mice (Figure 7A). FXR–/–
mice showed lower BMD than FXR+/+ mice (Figure 7B).
In addition, OVX-induced structural bone alterations,
including decreases in BV/TV, Tb.Th, Tb.N, and SMI,
were heightened by lack of FXR (Figure 7C–7F). No
significant difference was seen in Tb.Sp between FXR+/+
and FXR−/− mice after OVX (Figure 7G). These data
demonstrated that FXR deficiency strengthened the OVXinduced bone loss in vivo. Taken together, out data suggest
that FXR could be a pivotal modulator of bone loss in vivo
under pathological conditions.

DISCUSSION
In this study, we suggest a novel role of FXR, a
bile acid-sensing member of the nuclear receptor family,
as a negative regulator of RANKL-induced osteoclast
differentiation. We found that RANKL down-regulates
FXR expression during osteoclast differentiation.
Overexpression of FXR in BMMs attenuates RANKLinduced osteoclast differentiation by down-regulation
of NFATc1, which is a key modulator for osteoclast
differentiation. In agreement with this, FXR−/− mice
exhibited a significantly increased number of osteoclasts,
which was partly attributed to a severe osteoporotic
phenotype. In an attempt to elucidate the mechanisms
by which FXR deficiency increases the osteoclastic
differentiation, we demonstrated that the phosphorylation
of JNK1/2 by RANKL as well as the expression of JNK1/2
were decreased in FXR−/− BMMs. We found that the downregulation of JNK activity increased the expression of
PPARγ and PGC-1β, which might accelerate osteoclast
formation in FXR−/− BMMs.
The JNKs are members of the MAPK family
and are activated by environmental stress [34]. The
mammalian JNKs are encoded by three distinct genes
(Jnk1, Jnk2, and Jnk3). JNK1 and JNK2 isoforms
are ubiquitously expressed, whereas JNK3 is almost
exclusively found in the brain, heart and testis [34].
Many previous studies have reported the role of JNK1/2
in osteoclast formation. In mouse BMMs, JNK activity
is required during osteoclastogenesis to maintain the
status of osteoclastic commitment [35]. A study using
JNK1−/− mice has also reported that activation of JNK1
is required for the efficient osteoclastogenesis of BMMs
[36]. However, the present study is distinct from previous
genetic and pharmacological studies that investigated the
effects of a complete JNK blockade. In the present study,
although FXR deficiency failed to effectively induce
JNK phosphorylation by RANKL, the basal level of
JNK phosphorylation was still maintained in BMMs. We
speculate that the maintenance JNK phosphorylation at a

FXR deficiency accelerates unloading- or OVXinduced bone loss in vivo
We showed that FXR has an important role in OC
differentiation and bone remodeling under physiological
conditions. Next we used an unloading- or OVX-induced
bone loss model in order to determine whether deletion of
FXR affects bone loss under pathological conditions.
The effect of unloading was first investigated in
FXR-deficient mice, using tail suspension as a model of
hindlimb unloading [33]. FXR+/+ and FXR−/− mice were
subjected to tail suspension at age 8 weeks, and their
skeletal response was analyzed 1 week later. Unloading
induced a significantly greater femoral bone loss in FXR–/–
mice than in FXR+/+ mice (Figure 6A). In agreement, BMD
was significantly lower in FXR–/– mice than in FXR+/+ mice
after hindlimb unloading (Figure 6B). As FXR deﬁciency
accelerates the unloading-induced reduction in BMD
levels, we next examined the effects FXR deﬁciency on
the microstructural bone deterioration that is induced by
hindlimb unloading. Three dimensional micro-CT analyses
revealed that the level of BV/TV in the metaphyseal
region of the femur was reduced by hindlimb unloading in
FXR+/+ mice, and FXR deﬁciency significantly increased
the unloading-induced reduction in BV/TV (Figure 6C).
Other bone parameters, including Tb.Th, Tb.N, Tb,Sp,
and SMI, also confirmed more severe bone loss by
hindlimb unloading in FXR−/− mice compared to FXR+/+
mice (Figure 6D–6G). Furthermore, osteoclastogenesis
was increased in bone marrow (Figure 6H) or BMM
cells (Figure 6I) from FXR-/- mice, in comparison to
those from FXR+/+ mice after tail-suspension. These data
demonstrated that FXR deficiency accelerates unloadinginduced bone loss in vivo.
www.impactjournals.com/oncotarget
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Figure 5: FXR deficiency down-regulates IFN-β signaling pathways via JAK3-STAT1. (A, E) BMMs from FXR+/+ and

FXR−/− mice were cultured with RANKL (200 ng/ml) for 24 h. The mRNA level was analyzed by real-time PCR with IFN-β or JAK3
primer. (B) BMMs from FXR+/+ and FXR−/− mice were serum-starved for 16 h and stimulated with RANKL (200 ng/ml) for the indicated
time. (F) BMMs from FXR+/+ and FXR−/− mice were cultured with RANKL (200 ng/ml) for the indicated time. Cell lysates were then
subjected to western blot analysis with anti-p-STAT1 or anti-JAK3 antibody. (C, D) BMMs were infected by mock or FXR through a
retrovirus packaging system. Infected BMMs were stimulated with RANKL (200 ng/ml) for 4 or 24 h. The mRNA levels of IFN-β and
p-STAT1 were analyzed by real-time PCR or western blotting. (G) BMMs from FXR+/+ mice were cultured with RANKL (100 ng/ml) in the
presence of tofacitinib, a JAK3 inhibitor, for 3 days. TRAP+ MNCs were counted as osteoclasts when more than 3 nuclei were present. Scale
bar, 200 μm. (H) FXR+/+ BMMs were transfected with 40 nM siRNA. The siRNA-transfected FXR+/+ BMMs were cultured with RANKL
(200 ng/ml) for 3 days, and then TRAP+ osteoclasts were counted. (I) The siRNA-transfected FXR+/+ BMMs were serum-starved for 16 h
and stimulated with RANKL (200 ng/ml) for 4 h. (J) The siRNA-transfected FXR+/+ BMMs were cultured with RANKL (200 ng/ml) for
24 h. Cell lysates were then subjected to western blotting analysis with anti-p-STAT1 or anti-NFATc1 antibody. Data are expressed as mean
± SD from at least three independent experiments. Scale bar, 200 μm. *p < 0.05.

basal level permits the acceleration of osteoclastogenesis
by increased PPARγ-PGC-1β expression.
There is much evidence to show that the nuclear
receptor PPARγ regulates skeletal homeostasis through its
direct effect on osteoclasts [25, 30, 37, 38]. Genetically, the
loss of PPARγ function in mouse hematopoietic lineages
causes osteoclast defects, which present as osteopetrosis [25].
Pharmacologically, rosiglitazone-induced PPARγ activation
causes bone loss in mice by enhancing osteoclastogenesis
and bone resorption in vivo [25]. PPARγ modulates
transcription through the ligand-mediated recruitment of
coactivators [39]. PGC-1β (also known as Ppargc1β) is
a transcriptional coactivator and is strongly induced by
RANKL and rosiglitazone during osteoclast differentiation
[37, 39]. Knockdown of PGC-1β in vitro inhibits osteoclast
differentiation, and global PGC-1β deletion in mice results
in increased bone mass due to defects in osteoclasts [40].
Furthermore, targeted deletion of PGC-1β in the osteoclast
lineage resulted in complete resistance to rosiglitazoneinduced bone loss in vivo and severe attenuation of
rosiglitazone-stimulated osteoclastogenesis ex vivo [39].
In accord with these studies, we suggested that the upregulation of PPARγ and PGC-1β in FXR−/− BMMs might
lead to increased osteoclast formation and bone resorption in
vitro and in vivo. We further demonstrated that the increased
expressions of PPARγ and PGC-1β were caused by the
reduction of JNK1/2 in FXR−/− BMMs. Indeed, a previous
report demonstrated that PPARγ mRNA levels were increased
in JNK1/2-deficient cells, using microarray analysis [41],
confirming our present results. To our knowledge, the present
study is the first to demonstrate JNK-mediated negative
regulation of osteoclastogenesis via PPARγ and PGC-1β.
It has been reported that IFN-β limits the excessive
activation of osteoclast differentiation upon RANKL
stimulation in a feedback-regulated manner [31]. In
fact, IFN-β-knock-out mice exhibited an osteoporotic
phenotype due to augmented osteoclastogenesis,
indicating that IFN-β plays a critical role in the negative
regulation of osteoclastogenesis for bone homeostasis
[42]. Furthermore, STAT1 has been suggested as a
mediator of IFN-β during osteoclastogenesis because
STAT1-deficient BMMs are resistant to the suppression
of osteoclast differentiation by IFN-β [31, 42]. In
this study, it was demonstrated that FXR deficiency
www.impactjournals.com/oncotarget

impaired the negative regulation of IFN-β signaling in
osteoclastogenesis. We also found that FXR acts through
JAK3 to modulate IFN-β signaling, since the lack of
induction of JAK3 in FXR−/− BMMs correlated with the
resistance to the negative regulatory effects of IFN-β on
osteoclastogenesis. These data provide new insights into
the role of JAK3 in RANKL-induced osteoclast formation.
Taken together, FXR is important to maintain homeostatic
osteoclast differentiation through negative regulation of
the PPARγ and PGC-1β pathways and positive regulation
of the IFN-β and STAT1 pathways.
In addition to the role of FXR in physiological
conditions, we also found that FXR modulates
osteoclastogenesis and bone loss in pathological conditions
caused by unloading or estrogen withdrawal. The world
population is aging and the proportion of individuals over
65 is increasing [43]. Considering that menopause occurs
around the age of 50, millions of women will live many
years at risk for osteoporosis and fractures. Furthermore,
in a super-aged society, unloading-induced osteoporosis
is also a critical issue in bedridden patients with reduced
locomotor function. Thus, an understanding of the
molecular mechanisms of menopause- and unloadinginduced osteoporosis is required. In this study, our data
demonstrated that FXR has potential as a novel drug
target for preventing postmenopausal osteoporosis and
unloading-induced bone loss.
In summary, we have proposed a new regulatory
role of FXR in osteoclastogenesis (Figure 7H) in
physiological and pathological bone loss associated with
postmenopausal osteoporosis and disuse-induced bone
loss. Identification and elucidation of key mediators of
RANKL should aid in the development of therapeutic
strategies for the treatment of such skeletal diseases.

MATERIALS AND METHODS
Reagents
Guggulsterone, SP600125, and rosiglitazone were
purchased from Cayman Chemical Company (Ann Arbor,
MI, USA). Tofacitinib (JAK3 inhibitor) was purchased
from LC Laboratories (Woburn, MA, USA). Antibodies
against p-JNK and JNK were purchased from Cell
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Signaling Technology (Beverly, MA, USA). Antibodies
against NFATc1 and JAK3 were purchased from Santa
Cruz (Santa Cruz, CA, USA). Recombinant murine
M-CSF and RANKL were purchased from Peprotech
(Rocky Hill, NJ, USA). All other reagents were purchased
from Sigma-Aldrich (St. Louis, MO, USA).

FXR–/– mice were generously provided by F.
Gonzalez (NIH, Bethesda, Maryland, USA) and
backcrossed to a C57BL/6J background for 10
generations. Genotyping of the mice was performed

Figure 6: FXR deficiency accelerates unloading-induced bone loss in vivo. Male 8-week-old FXR+/+ and FXR−/− mice were
subjected to tail suspension, and mouse femurs were collected after 1 week. (A) Two-dimensional micro-CT images of the distal metaphysis
of the femurs. (B–G) Various bone parameters of femurs were analyzed by micro-CT. BMD (g/cm3) (B), BV/TV (%) (C), Tb.Th (μm) (D),
Tb.N (/μm) (E), Tb.Sp (μm) (F), SMI (G). (H–I) bone marrow cells (H) or BMMs (I) from FXR+/+ and FXR−/− mice were cultured with
RANKL (100 ng/ml) and M-CSF (30 ng/ml) for 4 days and then TRAP+ osteoclasts were counted. *p < 0.05, **p < 0.01.
www.impactjournals.com/oncotarget
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Figure 7: FXR deficiency accelerates OVX-induced bone loss in vivo. Female 12-week-old mice underwent either OVX or sham

operation, and mouse femurs were collected after 10 weeks. (A) Two-dimensional micro-CT images of the distal metaphysis of the femurs.
(B) BMD (g/cm2) of femur from FXR+/+ and FXR−/− mice was analyzed by DXA. (C–G) Various bone parameters of femurs were analyzed
by micro-CT. BV/TV (%) (C), Tb.Th (mm) (D), Tb.N (/mm) (E), SMI (F), Tb.Sp (mm) (G). (I) A simplified model for the role of FXR in
osteoclastogenesis. *p < 0.05, **p < 0.01. N.S.: Not Significant.
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as previously described [22]. Mouse littermates with
a genotype of C57BL/6J WT (FXR+/+) were used as
controls. All mice were maintained in the animal facility
of the Sookmyung Women’s University on a 12:12-h lightdark cycle, and were allowed food and water ad libitum.
All experiments were performed in accordance with the
institutional guidelines approved by the Sookmyung
Women’s University Animal Care and Use Committee.

glyceraldehyde 3-phosphate dehydrogenase (GAPDH)
expression.

Immunoblot analysis
Cells were lysed in lysis buffer (50 mM Tris HCl, pH
7.5, 150 mM NaCl, 1% NP-40, 1 mM EDTA, 0.25% SDS,
1 mM NaF, 1 mM Na3VO4, 1 mM phenylmethylsulfonyl
fluoride, pepstatin, leupeptin, and aprotinin) and were
clarified by centrifugation. Protein was measured by
Bradford assay (Bio-Rad Laboratories, Inc., Benicia, CA,
USA), and equal amounts of protein were separated by
sodium dodecyl sulfate-polyacrylamide gel electrophoresis
(SDS-PAGE) and transferred onto a polyvinylidene
fluoride (PVDF) membrane (Immobilon-P; Millipore,
Bedford, MA, USA). The membranes were blocked with
5% nonfat-milk in phosphate-buffered saline with 0.1%
Tween 20 (PBS-T) and then immunostained with the
indicated antibodies. The membranes were developed using
an enhanced chemiluminescence detection kit (Amersham
Biosciences, Buckinghamshire, United Kingdom).

Cells and culture system
Mouse bone marrow cells were isolated from
10–12-week-old FXR+/+ or FXR−/− C57BL/6J background
mice. Bone marrow cells were cultured in complete
α-MEM containing 10% (v/v) fetal bovine serum (FBS),
supplemented with 5 ng/ml recombinant murine M-CSF
(PeproTech) for 12 h to separate adherent and nonadherent cells. The non-adherent cells were then harvested
and cultured with 30 ng/ml M-CSF. After 4 days of
culturing, the floating cells were removed and the attached
cells were used as BMMs. All cells were cultured in
α-MEM containing 5% (v/v) FBS at 37°C in a humidified
atmosphere in 5% CO2 conditions.

Bone resorption assay
BMMs were differentiated on dentin slices with
M-CSF and RANKL (PeproTech, Inc., Rocky Hill,
NJ, USA) for 8 days. The cells were removed from the
dentin slice by wiping the its surface, and then the slices
were stained with toluidine blue (1 μg/ml; J.T. Baker,
Philipsburg, NJ, USA). The number of pits formed by
bone resorption on the dentin slices was counted. Image
analysis was accomplished using ImageJ software (version
1.32; National Institute of Health, Bethesda, MD, USA)
according to the manufacturer’s protocol.

TRAP staining of osteoclasts
Osteoclasts were observed by staining for TRAP
activity. Cultured cells were fixed with 10% formalin for
10 min, permeabilized with ethanol:acetone (50:50 v/v)
for 1 min at room temperature, and incubated in acetate
buffer (pH 5.2) containing naphthol ASMX phosphate
(Sigma-Aldrich) as the substrate and Fast Red Violet LB
salt (Sigma-Aldrich) as the dye for the reaction product
in the presence of 50 mM sodium tartrate. After washing
with distilled water and drying, TRAP+ MNCs (n > 3) were
counted using a light microscope.

Retroviral gene transduction
To generate retroviral stocks, pMX-IRES-FXR was
transfected into the packaging cell line Platinum-E (Plat-E.
kindly provided by Prof. S. Y. Lee at Ewha University).
Viral supernatant was collected from culture media at 48
h after transfection using Lipofectamine 2000 (Invitrogen,
Carlsbad, CA, USA) according to the manufacturer’s
instructions. For infection with retroviruses, BMMs were
incubated with the viral supernatant (4 ml/dish), polybrene
(10 µg/ml, Santa Cruz, CA, USA), and M-CSF (30 ng/ml)
for 2 days, and selected by puromycin (2 µg/ml; SigmaAldrich, St. Louis, MO, USA) for an additional 48 h.

Quantitative real-time PCR
Total RNA was purified with easy-BLUE (iNtRON
Biotechnology, Seoul, Korea), and cDNA was prepared
from 5 μg of RNA using Revert Aid™ First-Strand cDNA
Synthesis Kit (Fermentas, Glen Burnie, MD, USA).
Primers for osteoclastogenic genes used in this study are
shown in Supplementary Table 1. Real-time PCR reactions
were performed in a total volume of 20 μl, using SYBR®
Green PCR Master Mix (Applied Biosystems, Foster
City, CA, USA) according to the manufacturer’s protocol.
Thermocycling was performed using a 7500 real-time
PCR System (Applied Biosystems) with the following
conditions: initial hold at 95°C for 10 min, followed by 40
cycles of denaturation at 95°C for 15 s, annealing at 58°C,
and extension at 60°C for 1 min. Data were analyzed using
7500 System Sequence Detection Software version 2.0
(Applied Biosystems). An index mRNA level was assessed
using a threshold cycle (Ct) value and normalized against
www.impactjournals.com/oncotarget

siRNA transfection
BMMs were seeded into 48-well plates at
a density of 3.5 × 104 cells/well with 30 ng/ml
M-CSF. After 24 h, cells were transfected with 40
nM mouse JNK on-target plus smart pool siRNAs
(5′-AAAGAATGTCCTACCTTCT-3′)
(QIAGEN,
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Hilden, Germany) or mouse JAK3 on-target plus smart
pool siRNAs (5′-CACGTTAGACTTTGCCATCCA-3′;
QIAGEN) using Lipofectamine 2000 (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s instructions. The
control contained 40 nM non-targeting siRNA (QIAGEN).
The transfection took place in 2.5 ml of serum-free medium
for 6 h; the cells were then cultured for 4 days in complete
media containing 30 ng/ml M-CSF and 100 ng/ml RANKL
for osteoclast formation.

Female 12-week-old FXR+/+ and FXR−/− mice
underwent either ovariectomy (OVX) or sham operation
(n = 14 per group). The mice were euthanized after 10
weeks. Femurs of mice were fixed with 70% ethanol
at 4°C and were analyzed by DXA and micro-CT as
mentioned above.

Statistical analysis

LPS-induced osteoclast formation in vivo

The descriptive statistics present data as the mean
± SD. Means were compared by Student’s t-test (for
comparison of two means) or ANOVA (for multiple
comparisons) with a least significant difference post
hoc test. Data represent the means and the SD from at
least three independent experiments. Data were reported
as statistically significant when the p-value < 0.05 for
comparisons. Calculations were performed with the
software package SPSS (Ver. 21.0 for windows; SPSS,
Inc., Chicago, IL, USA).

To investigate the contribution of FXR to LPSinduced osteoclast formation in vivo, 12-week-old FXR+/+
and FXR−/− male mice were directly injected with 0.5
mg/mouse LPS on calvarial bone (n = 5 per each group).
After 6 days, mice were euthanized. Whole calvaria
were fixed in 4% paraformaldehyde for 24 h and then
stained with TRAP. Image analysis was accomplished
using ImageJ software (version 1.32; National Institute
of Health, Bethesda, MD, USA) according to the
manufacturer’s protocol.
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12-week-old male FXR+/+ and FXR−/− mice were
orally administered daily either with rosiglitazone (10
mg/kg; Cayman Chemical Company, Ann Arbor, MI,
USA) or with control (n = 10 per each group). The
mice were euthanized 2 months after administration.
Femurs of mice were fixed with 70% ethanol at 4°C until
analysis. Bone mineral density (BMD; g/cm2) of femurs
was measured and analyzed by the dual energy X-ray
absorptiometry (DXA) instrument PIXIMUS (GE Lunar,
Madison, WI, USA). Three-dimensional measurements
were performed with a micro-CT scanner and associated
analysis software (Model 1172; Skyscan, Antwerp,
Belgium) at 9-mm voxel size. Image acquisition was
performed at 35 kV of energy and at an intensity of 220
mA. The threshold was set to segment the bone from the
background, and the same threshold setting was used for
all samples.
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